Our top pick for
Calyxt, Inc is a packaged foods business based in the US. Calyxt shares (CLXT) are listed on the NASDAQ and all prices are listed in US Dollars. Calyxt employs 75 staff and has a trailing 12-month revenue of around USD$11.4 million.
Since the stock market crash in March caused by coronavirus, Calyxt's share price has had significant negative movement.
Its last market close was USD$3.58, which is 40.03% down on its pre-crash value of USD$5.97 and 49.17% up on the lowest point reached during the March crash when the shares fell as low as USD$2.4.
If you had bought USD$1,000 worth of Calyxt shares at the start of February 2020, those shares would have been worth USD$529.73 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$625.89.
|Latest market close||USD$3.58|
|52-week range||USD$2.4 - USD$8.41|
|50-day moving average||USD$5.5026|
|200-day moving average||USD$5.0009|
|Wall St. target price||USD$6.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.004|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||2.29%|
|1 month (2020-10-23)||-3.50%|
|3 months (2020-08-25)||-28.40%|
|6 months (2020-05-22)||-20.97%|
|1 year (2019-11-25)||-1.65%|
|2 years (2018-11-23)||-69.84%|
|3 years (2017-11-24)||-82.01%|
|5 years (2015-11-22)||N/A|
|Revenue TTM||USD$11.4 million|
|Gross profit TTM||USD$-1,984,000|
|Return on assets TTM||-32.32%|
|Return on equity TTM||-72.41%|
|Market capitalisation||USD$129.4 million|
TTM: trailing 12 months
There are currently 491,932 Calyxt shares held short by investors – that's known as Calyxt's "short interest". This figure is 5% down from 517,925 last month.
There are a few different ways that this level of interest in shorting Calyxt shares can be evaluated.
Calyxt's "short interest ratio" (SIR) is the quantity of Calyxt shares currently shorted divided by the average quantity of Calyxt shares traded daily (recently around 82816.835016835). Calyxt's SIR currently stands at 5.94. In other words for every 100,000 Calyxt shares traded daily on the market, roughly 5940 shares are currently held short.
However Calyxt's short interest can also be evaluated against the total number of Calyxt shares, or, against the total number of tradable Calyxt shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Calyxt's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Calyxt shares in existence, roughly 10 shares are currently held short) or 0.0753% of the tradable shares (for every 100,000 tradable Calyxt shares, roughly 75 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Calyxt.
Find out more about how you can short Calyxt stock.
We're not expecting Calyxt to pay a dividend over the next 12 months.
Over the last 12 months, Calyxt's shares have ranged in value from as little as $2.4 up to $8.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calyxt's is 2.286. This would suggest that Calyxt's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. The company offers high oleic soybean products, including oil and meal. It also develops high fiber wheat; improved digestibility alfalfa; and cold storable potatoes. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was founded in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.